Main Street Capital (MAIN) Earnings Expected to Grow: Should You Buy? — Neutral
MAIN Zacks Investment Research — October 30, 2025Main Street Capital (MAIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MasterCraft Boat Holdings, Inc. (MCFT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release — Positive
MCFT Zacks Investment Research — October 30, 2025MasterCraft Boat Holdings, Inc. (MCFT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Monster Beverage (MNST) Earnings Expected to Grow: What to Know Ahead of Q3 Release — Positive
MNST Zacks Investment Research — October 30, 2025Monster Beverage (MNST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Kenvue (KVUE) Q3 Earnings Expected to Decline — Negative
KVUE Zacks Investment Research — October 30, 2025Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
M/A-Com (MTSI) Earnings Expected to Grow: Should You Buy? — Neutral
MTSI Zacks Investment Research — October 30, 2025M/A-Com (MTSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? — Positive
NKTR Zacks Investment Research — October 30, 2025Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline — Negative
MRNA Zacks Investment Research — October 30, 2025Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Opendoor Technologies Inc. (OPEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release — Negative
OPEN Zacks Investment Research — October 30, 2025Opendoor Technologies (OPEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will PENN Entertainment (PENN) Report Negative Earnings Next Week? What You Should Know — Negative
PENN Zacks Investment Research — October 30, 2025PENN Entertainment (PENN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Planet Fitness (PLNT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release — Positive
PLNT Zacks Investment Research — October 30, 2025Planet Fitness (PLNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Nomad Foods (NOMD) to Report a Decline in Earnings: What to Look Out for — Negative
NOMD Zacks Investment Research — October 30, 2025Nomad Foods (NOMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Primo Brands (PRMB) Reports Next Week: Wall Street Expects Earnings Growth — Positive
PRMB Zacks Investment Research — October 30, 2025Primo Brands (PRMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RPC, Inc. ( RES ) Q3 2025 Earnings Call October 30, 2025 9:00 AM EDT Company Participants Michael Schmit - VP, CFO, Treasurer & Corporate Secretary Ben Palmer - CEO, President & Director Conference Call Participants Donald Crist - Johnson Rice & Company, L.L.C., Research Division Presentation Operator Good morning, and thank you for joining us for RPC Inc.'s Third Quarter 2025 Earnings Conference Call.
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? — Positive
PTGX Zacks Investment Research — October 30, 2025Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet (PODD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release — Neutral
PODD Zacks Investment Research — October 30, 2025Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Runway Growth Finance Corp. (RWAY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Positive
RWAY Zacks Investment Research — October 30, 2025Runway Growth Finance Corp. (RWAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sanuwave Health Inc. (SNWV) to Report Q3 Results: Wall Street Expects Earnings Growth — Positive
SNWV Zacks Investment Research — October 30, 2025Sanuwave Health (SNWV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
There are plenty of asset classes that are conducive to active management. But emerging markets debt is arguably near the top of the list.
Rithm Capital Corp. (RITM) Q3 2025 Earnings Call Transcript — Neutral
RITM Seeking Alpha — October 30, 2025Rithm Capital Corp. ( RITM ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Emma Bolla - Associate General Counsel Michael Nierenberg - Chairman, President & CEO Nicola Santoro - CFO, Chief Accounting Officer & Treasurer Baron Silverstein - President Conference Call Participants Crispin Love - Piper Sandler & Co., Research Division Bose George - Keefe, Bruyette, & Woods, Inc., Research Division Eric Hagen - BTIG, LLC, Research Division Jason Weaver - JonesTrading Institutional Services, LLC, Research Division Trevor Cranston - Citizens JMP Securities, LLC, Research Division Presentation Operator Good morning, and welcome to the Rithm …
Wall Street Analysts See a 234.66% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? — Positive
DAWN Zacks Investment Research — October 30, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 234.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
